Elevation mechanisms and diagnostic consideration of cardiac troponins under conditions not associated with myocardial infarction. Part 2

AM Chaulin - Life, 2021 - mdpi.com
This article proceeds with a discussion of the causes and mechanisms of an elevation in
cardiac troponins in pathological conditions not associated with acute myocardial infarction …

Role of cardiac biomarkers in cancer patients

GC Semeraro, CM Cipolla, DM Cardinale - Cancers, 2021 - mdpi.com
Simple Summary Cardiac biomarkers have proved increasingly useful in the various
branches of cardiology, not sparing the field of cardio-oncology. With specific reference to …

Ultrasensitive upconversion nanoparticle immunoassay for human serum cardiac troponin I detection achieved with resonant waveguide grating

YT Tseng, YC Chiu, VD Pham, WH Wu, TT Le-Vu… - ACS …, 2024 - ACS Publications
Selective detection of biomarkers at low concentrations in blood is crucial for the clinical
diagnosis of many diseases but remains challenging. In this work, we aimed to develop an …

Multicenter, prospective, randomized controlled trial of high-sensitivity cardiac troponin I–guided combination angiotensin receptor blockade and beta-blocker therapy …

PA Henriksen, P Hall, IR MacPherson, SS Joshi… - Circulation, 2023 - Am Heart Assoc
BACKGROUND: Anthracycline-induced cardiotoxicity has a variable incidence, and the
development of left ventricular dysfunction is preceded by elevations in cardiac troponin …

Cancer therapy-related cardiac dysfunction: is endothelial dysfunction at the heart of the matter?

C Ching, D Gustafson, P Thavendiranathan… - Clinical …, 2021 - portlandpress.com
Significant improvements in cancer survival have brought to light unintended long-term
adverse cardiovascular effects associated with cancer treatment. Although capable of …

New insights in the era of clinical biomarkers as potential predictors of systemic therapy-induced cardiotoxicity in women with breast cancer: a systematic review

A Alexandraki, E Papageorgiou, M Zacharia… - Cancers, 2023 - mdpi.com
Simple Summary Cancer therapy-related cardiac dysfunction (CTRCD) has been an urgent
medical issue in patients that receive breast cancer therapies including anthracycline-based …

[HTML][HTML] Cardiotoxicity in cancer patients treated with chemotherapy: A systematic review

MAC Lima, HR de Almeida Brito… - … journal of health …, 2022 - ncbi.nlm.nih.gov
Objective: The objective of the study was to assess the incidence of chemotherapy
cardiotoxicity. Methods: This is a systematic review carried out through the PubMed, VHL …

Severe cardiac toxicity induced by cancer therapies requiring intensive care unit admission

A Montisci, V Palmieri, JE Liu, MT Vietri… - Frontiers in …, 2021 - frontiersin.org
A steadying increase of cancer survivors has been observed as a consequence of more
effective therapies. However, chemotherapy regimens are often associated with significant …

[HTML][HTML] Assessment of prognostic value of high-sensitivity cardiac troponin t for early prediction of chemoradiation therapy-induced cardiotoxicity in patients with non …

T Xu, QH Meng, SC Gilchrist, SH Lin, R Lin, T Xu… - International Journal of …, 2021 - Elsevier
Purpose Cardiotoxicities induced by cancer therapy can negatively affect quality of life and
survival. We investigated whether high-sensitivity cardiac troponin T (hs-cTnT) levels could …

Rationale and design of the Cardiac CARE Trial: a randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity

PA Henriksen, P Hall, O Oikonomidou… - Circulation: Heart …, 2022 - Am Heart Assoc
Background: Anthracyclines are effective cytotoxic drugs used in the treatment of breast
cancer and lymphoma but are associated with myocardial injury, left ventricular dysfunction …